Besifloxacin Hydrochloride
The hydrochloride salt of besifloxacin, a topical ophthalmic fluoroquinolone antibiotic used to treat bacterial eye infections. Applied as eye drops, it targets a wide range of bacteria responsible for conjunctivitis. It was specifically developed for ophthalmic use to minimize systemic exposure.
Peso Molecular
430,3000 g/mol
TPSA
86,90 Ų
Mecanismo de Ação
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Estrutura 2D
Cite this structure
Embed this structure
SMILES
Cl.N[C@@H]1CCCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1
InChI
InChI=1S/C19H21ClFN3O3.ClH/c20-15-16-12(18(25)13(19(26)27)9-24(16)11-4-5-11)7-14(21)17(15)23-6-2-1-3-10(22)8-23;/h7,9-11H,1-6,8,22H2,(H,26,27);1H/t10-;/m1./s1
Molecular Formula
C19H22Cl2FN3O3
HBD / HBA
3 / 7
Ligações Rotacionáveis
3
Átomos Pesados
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
The hydrochloride salt of besifloxacin, a topical ophthalmic fluoroquinolone antibiotic used to treat bacterial eye infections. Applied as eye drops, it targets a wide range of bacteria responsible for conjunctivitis. It was specifically developed for ophthalmic use to minimize systemic exposure.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription, and repair. This leads to breakage of bacterial chromosomal DNA and rapid cell death.
Yes, Besifloxacin Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201761. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10224595. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="besifloxacin-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/besifloxacin-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/besifloxacin-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/besifloxacin-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="besifloxacin-hydrochloride"></drugfyi-drug>